Japan Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers And Clinics, Home Care) - Forecasts From 2023 To 2028

  • Published : Apr 2023
  • Report Code : KSI061615168
  • Pages : 78

The Japan CGM market is expected to grow at a CAGR of 18.63%, from an initial value of US$169.365 million in 2021 to US$559.878 million by 2028.

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

Diabetes is a complicated, chronic condition that can lead to myocardial infarction, stroke, neuropathy, blindness, and renal damage. For patients to avoid aggravation and the beginning of problems, daily glucose level management is essential. With their recent development, real-time continuous glucose monitoring (CGM) apps have been created for smartphones and other devices connected to CGM systems. These CGM apps are also utilized in Japan. Using CGM applications enhances patients' blood glucose management as compared to conventional retrospective CGM, which is anticipated to aid in slowing the course of type 2 diabetes mellitus (DM) and preventing complications. Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion.

Increasing patients with Type-1 and Type-2 diabetes in Japan to surge growth.

Type 1 also known as insulin-repaired diabetes is brought by immune system failure whereas Type 2 sometimes referred to as insulin-dependent diabetes is caused due to adoption of a sedentary lifestyle. Type 2 diabetes is prevailing in Japan due to the senior population. To prevent various diseases including renal issues, cardiovascular diseases, and other ailments the blood glucose level using continuous glucose monitoring is done. ?Another explanation is that more people have had their illnesses identified after being referred to a hospital due to the findings of a metabolic syndrome screening.

?CGM sensors are the prevailing factor for market growth.

CGM sensors are a prominent market shareholder. Hydrogen peroxide is formed when platinum reacts with glucose oxidase in the CGM sensor. Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion. CGM has been a popular substitute for portable finger-prick glucometers providing convenience to diabetic patients which will upsurge the market in Japan.

Market Key Developments

  • In December 2022, The Dexcom G6 CGM System now has increased payment coverage under the Japanese medical insurance system, according to a Terumo Company announcement. A larger population of patients with diabetes will be able to get reimbursement utilizing the Dexcom G6 CGM System in Japan thanks to the recently created category of "C150."
  • In March 2022, The Japanese Ministry of Health, Labour, and Welfare has given the go-ahead for the FreeStyle® Libre system's reimbursement coverage to be expanded to encompass all diabetics who take insulin at least once per day, according to a statement released by Abbott.


  • By Application
    • Diabetes Patients
    • Critical Patients
  • By End-User Industry
    • Hospitals
    • Diagnostic Centers & Clinics
    • Home Care


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients


6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care


7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix


8.1. Dexcom, Inc.

8.2. Abbott Laboratories

8.3. Medtronic plc

8.4. Nipro Corporation

8.5. Panasonic Healthcare Co., Ltd.

8.6. Terumo Corporation

8.7. Roche Diabetes Care, Inc.

8.8. Omron Healthcare Co., Ltd.

8.9. Fukuda Denshi Co., Ltd.

8.10. Arkray, Inc.

Dexcom, Inc.

Abbott Laboratories

Medtronic plc

Nipro Corporation

Panasonic Healthcare Co., Ltd.

Terumo Corporation

Roche Diabetes Care, Inc.

Omron Healthcare Co., Ltd.

Fukuda Denshi Co., Ltd.

Arkray, Inc.